Moleculin Executes 1-for-20 Reverse Split to Regain Nasdaq Compliance
MBRX is trading near its 52-week low of $3.228 (91% below the low).
Summary
Moleculin's 1-for-20 reverse split became effective October 20, 2026, cutting outstanding shares to about 1.05 million to address its Nasdaq bid-price deficiency. The move does not resolve going-concern doubts or the need for substantial new financing.
Key Events · Corporate Governance and Compliance · MBRX
-
1-for-20 Reverse Split Effective
The reverse split took effect at 12:01 a.m. ET on October 20, 2026; shares trade post-split under MBRX with new CUSIP 60855D507.
-
Share Count Cut to ~1.05 Million
Outstanding shares fell from approximately 20.91 million to approximately 1.05 million, while authorized shares remain at 500 million.
-
Nasdaq Bid-Price Deficiency Remains the Driver
The split follows the September 15, 2026 Nasdaq Staff Determination Letter finding the company non-compliant with the minimum bid price rule.
-
Going Concern and Financing Risk Persist
The company reiterates it will require significant additional financing with no commitments in place, and going-concern doubt was previously disclosed in the August 13, 2026 10-Q.
Analysis · MBRX · Life Sciences
The 1-for-20 reverse split took effect today, collapsing the share count from about 20.91 million to roughly 1.05 million. It is the company's attempt to cure the Nasdaq minimum bid price deficiency disclosed on September 18, 2026, but it does not fix the underlying problem: Moleculin still carries going-concern doubt and needs significant additional financing with no commitments in place. Mechanically, the split lifts the per-share price while leaving 500 million authorized shares untouched, so the enormous share headroom remains available for future dilution.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $3.23 to $315.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.